Forest Sues Torrent, Watson, Glenmark Over Bystolic Generic
By Sophia Pearson – Mar 14, 2012 11:33 AM ET
Forest Laboratories Inc. (FRX) sued Torrent Pharmaceuticals Ltd., Watson Pharmaceuticals Inc. (WPI), Glenmark Pharmaceuticals Ltd. (GNP) and two other drugmakers claiming they seek to sell a generic version of the hypertension pill Bystolic before a U.S. patent expires.
Forest is the exclusive licensee for the patent issued to Johnson & Johnson (JNJ)’s Janssen Pharmaceutica in 2003. The generic drugmakers filed for permission to sell versions of the drug’s 2.5-milligram, 5-milligram, 10-milligram and 20-milligram capsules, according to the complaint filed yesterday in federal court in Wilmington, Delaware.
Bystolic, a once-daily treatment, contains nebivolol hydrochloride and is used for the treatment of high blood pressure. The drug was introduced in the U.S. in 2008.
Sanjay Gupta, chief executive officer of Torrent’s U.S. subsidiary, didn’t immediately return a phone call seeking comment on the lawsuit. Charlie Mayr, a spokesman for Watson, also didn’t immediately return a phone call seeking comment. Officials at Glenmark weren’t immediately available for comment.
The case is Forest Laboratories Inc. v. Torrent Pharmaceuticals Ltd. (TRP), 12-00305, U.S. District Court District, of Delaware (Wilmington).
To contact the reporter on this story: Sophia Pearson in Philadelphia at email@example.com.
To contact the editor responsible for this story: Michael Hytha at firstname.lastname@example.org.